Impact of Clinician-administered Vaginal Live Biotherapeutic Product

Open-label, Single-arm Study to Assess the Colonization Kinetics of Clinician- Administered Vaginal Live Biotherapeutic Product Containing Multiple Strains of Lactobacillus Crispatus.

This is an open-label, single-arm, Phase Ib trial assessing the consistency of response and colonization kinetics of a vaginally inserted live biotherapeutic intervention with optimized adherence.

In this study investigators will enroll participants from the VIBRANT study who received active study product and test the vaginal microbiome. If a participant does not have a Lactobacillus predominant vaginal microbiome, they will re-dose with LC106 in the clinic for three days in a row. This will allow understanding of how consistent the response to LC106 is, and whether directly monitored administration improves results.

Inclusion Criteria:

• Previous participant in the VIBRANT study, randomized to active LBP
• Nugent score 4-10

Exclusion Criteria:

• Infection requiring antibiotics detected on screening labs
• Use of oral or vaginal antibiotics in the 30 days prior to screening
• Use of an oral or vaginal probiotic in the 30 days prior to screening